Liver_diseases
Associations of Coexisting Metabolic Dysfunction-Associated Steatotic Liver Disease and Sarcopenia-Related Abnormalities With Adverse Clinical Outcomes Across Obesity States.
Metabolic dysfunction-associated steatotic liver disease (MASLD) is associated with adverse liver and non-liver outcomes, but the impact of coexisting sarcopenia-related abnormalities (e.g., low muscle strength [MS], muscle mass, and physical performance) remains unclear. In a prospective UK Biobank cohort (n...
Prognostic performance of Asian Working Group for Sarcopenia 2019 and 2025 sarcopenia definitions in cirrhosis.
BACKGROUND/PURPOSE OF THE STUDY
The Asian Working Group for Sarcopenia (AWGS) updated its criteria in 2025, adding a body mass index (BMI)-adjusted muscle index (ASM/BMI) to the conventional skeletal muscle index (SMI). We aimed to compare the prognostic performances of the...
Inter-tissue relationships of gene expression in liver, muscle and adipose tissue of children with end-stage chronic liver disease.
OBJECTIVES
End-stage chronic liver disease in children is associated with sarcopenia and aberrant adipose tissue mass. We investigated correlations between liver pathology-associated gene pathways (fibrosis, inflammation and steatosis) and metabolic genes in muscle and adipose tissue.
METHODS
Liver, rectus abdominis muscle and subcutaneous...
Hepatokines lipocalin 2 and osteopontin drive muscle atrophy in MASH.
A bidirectional relationship exists between metabolic dysfunction-associated steatotic liver disease (MASLD) and its progressive inflammatory form, metabolic dysfunction-associated steatohepatitis (MASH), and sarcopenia, with each worsening the prevalence and prognosis of the other. Hepatokines have recently been shown to affect skeletal...
Prevalence and Prognostic Impact of the Coexistence of Cachexia and Sarcopenia in Patients With Chronic Liver Diseases.
BACKGROUND
Cachexia and sarcopenia are prevalent, inflammation-linked syndromes in chronic liver disease that worsen outcomes. To our knowledge, their coexistence in a single chronic liver disease cohort has not been systematically examined. In this study, we evaluated the prevalence, clinical features...
Systemic Drivers and Molecular Mechanisms of Sarcopenia in Aetiology-Specific End-Stage Liver Disease.
BACKGROUND
Patients with end-stage liver disease (ESLD) often present with sarcopenia, defined as loss of skeletal muscle mass and quality, which is associated with reduced quality of life and increased mortality. However, the molecular mechanisms driving sarcopenia in ESLD are not...
Comment on 'Effect of Skeletal Muscle Mass and Its Associated Mediators on the Development of Steatotic Liver Disease: A Cohort Study in China' by Liang et al.
Burden of malnutrition and sarcopenia in patients with cirrhosis: pathophysiology, assessment, and management.
Malnutrition and sarcopenia are highly prevalent and robustly associated with reduced quality of life, disease progression, and poor outcomes, including complications and mortality, in patients with cirrhosis. Their pathophysiology is multifactorial, involving inadequate dietary intake and malabsorption, impaired liver functional...
Sarcopenia and MASLD: novel insights and the future.
Metabolic dysfunction-associated steatotic liver disease (MASLD; previously known as non-alcoholic fatty liver disease) is the leading cause of chronic liver disease worldwide and is closely linked to the obesity epidemic. MASLD often coexists with sarcopenia, an age-related loss of muscle...
Effect of Skeletal Muscle Mass and Its Associated Mediators on the Development of Steatotic Liver Disease: A Cohort Study in China.
BACKGROUND
Understanding the relationship between relative skeletal muscle mass and newly proposed steatotic liver disease (SLD) is crucial, but research gaps still exist. Based on a cohort study, we investigated the impact of relative skeletal muscle mass on incident SLD and...
Sarcopenia and gender disparities in liver transplant waiting lists: evaluating predictive scores and delisting risks.
BACKGROUND
The model for end-stage liver disease (MELD) and model for end-stage liver disease-sodium (MELD-Na) scores are the most widely used for prioritizing patients on the liver transplant (LT) waiting list. However, the quality and accuracy of these scores are questionable....
Management of Children Awaiting Liver Transplantation: Sarcopenia, Cholestasis and Beyond.
Sarcopenia has been increasingly recognized as a risk factor for worse outcomes in liver transplantation; however, the data remain limited on pediatric-specific outcomes. These gaps in knowledge are in part due to the lack of a standardized definition, challenges inherent...
Impact of physical activities in metabolic dysfunction associated steatotic liver disease, sarcopenia, and cardiovascular disease.
There are no comprehensive studies that investigated differential effects of physical activity (PA) types on metabolic dysfunction associated steatotic liver disease (MASLD) and their associations with sarcopenia and cardiovascular disease. A cross-sectional analysis using data from 66,021 participants from the...
Integrated Multiomics Analyses of the Molecular Landscape of Sarcopenia in Alcohol-Related Liver Disease.
Skeletal muscle is a major target for ethanol-induced perturbations, leading to sarcopenia in alcohol-related liver disease (ALD). The complex interactions and pathways involved in adaptive and maladaptive responses to ethanol in skeletal muscle are not well understood. Unlike hypothesis-driven experiments,...
Severe Dietary Energy Restriction for Compensated Cirrhosis Due to Metabolic Dysfunction-Associated Steatotic Liver Disease: A Randomised Controlled Trial.
Compensated cirrhosis due to metabolic dysfunction-associated steatotic liver disease (CC-MASLD) increases morbidity and mortality risk but has no aetiology-specific treatment. We investigated the safety and efficacy signals of severe energy restriction. In this randomised controlled trial, adults with CC-MASLD and...
